Matinas BioPharma Holdings MTNB
NYSE MTNB
$1.59 -0.11 (-6.48%)
As of: Oct 21, 2026 · 3:59 PM EDT

Matinas BioPharma Holdings (MTNB) Current Deferred Revenue (2017)

Updated

Matinas BioPharma Holdings' Current Deferred Revenue came in at $29,937 for Q4 2017, down 60.0% from the prior quarter.

Analysis

Matinas BioPharma Holdings (MTNB) Current Deferred Revenue (2017) Analysis & Trends

Going back to Q1 2017, Matinas BioPharma Holdings' Current Deferred Revenue data covers 4 quarters.

  • Business Quant data shows MTNB's Current Deferred Revenue at $74,844 (Q3 2017), $119,750 (Q2 2017) and $164,656 (Q1 2017) in the three quarters before Q4 2017.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Matinas BioPharma Holdings 679,055.62 -11.91 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2017 29,937.00
Sep 30, 2017 74,844.00
Jun 30, 2017 119,750.00
Mar 31, 2017 164,656.00
API Access

Matinas BioPharma Holdings Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=MTNB&period=max&api_key=YOUR_API_KEY